

1 June 2018

NSX Announcement

Completion of Capital Raising and Issue of Shares

Beroni Group Limited (NSX:BTG) (“Beroni” or the “Company”) is pleased to announce that it has completed the placement of 3,751,887 fully paid ordinary shares at an issue price of A\$0.65 to raising A\$2,438,726 (“Tranche 2 Placement Shares”). Shareholders approved the issue of this Tranche 2 Placement Shares at the Annual General Meeting held on 30 May 2018.

Funds raised from the issue of Tranche 2 Placement Shares are for the investment in Dendrix Inc. (Japan), whereby Beroni is committing a further 12.48% interest for approximately \$2.435 million by 30 September 2018, subject to satisfaction of conditions precedent. For information about Beroni’s investment into Dendrix Inc. please refer to announcement dated 9 April 2018.

Notice given under section 708A(5) of the Corporations Act 2001 (Cth)

This notice is given by the Company under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) in relation to an issue of 3,751,887 fully paid shares by the Company without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this notice, the Company has complied with:

1. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
2. section 674 of the Corporations Act.

There is no excluded information as at the date of this notice, for the purposes of Section 708A (7) and (8) of the Corporations Act.

For further information please contact:

Mr Jacky Zhang
Executive Chairman
Tel: +86 1851 6931 911
E: 1710426553@qq.com

Mr Peter Wong
Non-Executive Director
Tel: +61 423 727 580
E: pwong@asiainvest.com.au

About Beroni Group Limited (NSX: BTG) (FSE:6B9)

Beroni Group is an Australian biotechnological company which is dual listed on the National Stock Exchange (Australia) and Frankfurt Stock Exchange. Its business mainly focuses on biotechnology, life sciences, environmental science and governance, precision medicine, regenerative medicine, and stem cell anti-cancer and anti-aging projects.



Beroni Group's currently has four main products: NicoBloc, Fogibloc, Multi Vigorous tablets (Bei Jingli) and Multi lung cleaning tablets (Bei Feiqing). Beroni Group's overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries. The Company is open to acquisition opportunities to expand the business and increase its market share.